Merz Aesthetics® Launches Ultherapy PRIME® in the EMEA Region at the 2025 IMCAS World Congress
New Data is presented in the field of regenerative aesthetics
Merz Aesthetics launches Ultherapy PRIME® in Europe, Middle East and Africa, an evolution of the non-invasive skin lifting Ultherapy® and presents six abstracts at the 2025 International Master Course on Aging Science (IMCAS) World Congress highlighting its product portfolio and its contribution to the field of regenerative aesthetics.
“Our new Ultherapy PRIME® device demonstrates our commitment to persist in innovation,” said Gonzalo Mibelli, EMEA President, Merz Aesthetics. “As one of the leaders in non-invasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform as a proven technology and customizable, long-lasting* treatment option.”
The focus of this year’s Merz Aesthetics Symposium at IMCAS is Regenerative Aesthetics. “Patients are looking for more sustainable ways to address aging with regenerative aesthetic treatments providing both preventive and restorative methods to improve skin health and enhance long-term confidence,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA at Merz Aesthetics. “By collaborating with experts in aesthetics and aging science, this year’s Congress enables us to showcase our advancements and leadership in this field.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics Symposium RegenX: Elevating Skin, Lifting Confidence. – Dr. Joyce Lim, Dr. Julia Sevi, Dr. Tatjana Pavicic, Dr. Omar Haroon, Dr. Daria Voropai, Saturday, February 1, 10:30 – 12:30
- Ultherapy PRIME® Golden Lounge:
- Opening with Dr. Sabrina Fabi, Thursday, January 30, 12:30
- Expert Roundtable “Non-invasive Regenerative Biostimulation” – Dr. Tatjana Pavicic, Dr. Kerstin Ortlechner, Dr. Sonja Sattler, Thursday, January 30, 14:30
- Expert Roundtable “Importance of Visualization” – Dr. Julia Sevi, Dr. Daria Voropai, Dr. Kerstin Ortlechner, Friday, January 31, 10:00
- Expert Talk “Truly non-invasive Regenerative Collagen Biostimulation” – Dr. Tatjana Pavicic, Dr. Alec McCarthy, Friday, January 31, 12:45
- IMCAS Product Analysis Session “HA Skinboosters” – Dr. Mimi Borelli, Global Medical Affairs, Merz Aesthetics, Thursday, January 30, 13:30 – 15:00
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO, Merz Aesthetics, Friday, January 31, 16:00 – 18:00
- IMCAS Product Analysis Session “Aesthetic Toxins: Pipeline & Future” – Andy Curry, PhD, Associate Medical Director, Merz Aesthetics, Saturday, February 1, 14:00 ‒ 15:30
Merz Aesthetics Booth Talks
- Connecting with Confidence: Global Insights for a more patient centered approach – Dr. Shannon Humphrey, Thursday, January 30, 14:30
- The power of synergy for challenging cases – Dr. Larisa Pfahl, Thursday, January 30, 15:30
- Standing out in a competitive marketplace: Building an influential brand in Aesthetics – Dr. Audrey Neff, Friday, January 31, 11:00
- 2 is better than 1: Optimizing Results – Dr. Chris Hutton, Friday, January 31, 13:00
- Synergistic strategies for décolleté treatment in mature patients – Dr. Marie-Eugénie Nichanian-Broglia, Friday, January 31, 13:30
- Enhancing Skin Quality: Case study and clinical outcome – Dr. Tatiana Kuznechenkova, Friday, January 31, 15:30
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the Congress and displayed on the virtual e-poster platform with detailed abstracts.
- CaHA microspheres stimulate proteoglycan expression, supporting improved skin quality and elasticity. Authors: Yoana Dimitrova, MSc; Christian Hartmann, PhD; Kristina Riegel, PhD; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl; PhD
- Exploring the mode of action of elastin stimulation by CaHA microspheres. Authors: Christian Hartmann, PhD; Kristina Riegel, PhD; Yoana Dimitrova, MSc; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl, PhD
- Global Perspectives on Aesthetic Treatments and Approaches for Skin Quality Improvement: Insights from an Expert Advisory Board. Authors: Martina Kerscher, MD; Kate Goldie, MD; Cyro Hirano, MD; Stephen Lowe, MD; Kavita Mariwalla, MD; Milton Moore, MD; Je Young Park, MD; Dusan Sajic, MD; Sonja Sattler, MD; Julieta Spada, MD; Vasanop Vachiramon, MD; Bianca Viscomi, MD
- Microfocused Ultrasound in Regenerative Aesthetics: A Narrative Review on Mechanisms of Action and Clinical Outcomes. Authors: Vasanop Vachiramon, MD; Tatjana Pavicic, MD; Gabriela Casabona, MD; Jeremy B. Green, MD; Jennifer Levine, MD; Je Young Park, MD; Julieta Spada, MD; Mariana Muniz, MD; John Akers, PharmD; Matthew Jackson, PhD; Alec McCarthy, PhD
- Arterioembolic Characteristics of Hyaluronic Acid and Calcium Hydroxylapatite Fillers within an Artificial Arterial Perfusion Model. Authors: Alec D. McCarthy, PhD; Danny J. Soares, MD; Akash Chandawarkar, MD; Julia Fedorova, MS-I; Yu Zhang, MS-I; Larry Blevins, PA-C; Alexis Bowhay, PA-C; Thomas J. Kean, PhD; David K. Funt, MD
- Extracellular Matrix Response to Diluted Calcium Hydroxylapatite Microspheres and Poly-L-Latic Acid Microparticles. Authors: Gabriela Casabona, MD; Kate Goldie, MD; Niamh Corduff, MD; Alec McCarthy, PhD; Korin Leffler, PhD; Thomas Hengl, PhD; Kristina Riegel, PhD
*results can last up to a year or more, Werschler et al. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;(9)2:27-33, Ulthera Instructions For Use.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2025 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera Inc. in the EU and/or certain other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123568990/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom